| Literature DB >> 29483834 |
Cheng Wang1,2, Haoye Meng1, Yu Wang1, Bin Zhao1,3, Chenyang Zhao4, Weijia Sun5, Yun Zhu1, Bingxing Han5, Xueling Yuan1, Ruoxi Liu1, Xin Wang6, Aiyuan Wang1, Quanyi Guo1, Jiang Peng1,2,5,3,6,4, Shibi Lu1.
Abstract
We explored the mechanism of early stage osteonecrotic femoral head collapse by analyzing and comparing different regions in human osteonecrotic femoral head samples. Eight osteonecrotic femoral heads (ARCO II-III) were obtained from patients undergoing total hip arthroplasty. Bone structure was observed and evaluated by micro-computed tomography (CT) scans and pathology. Osteoblast and osteoclast activities were detected by tartrate-resistant acid phosphatase, alkaline phosphatase, and immunofluorescent staining. Some trabeculae had microfractures in the subchondral bone and necrotic region, which had lower bone mineral density, as well as trabecular thickness and number, but greater osteoclast activity. A sclerotic band had already appeared in certain samples which had greater trabecular thickness and number, bone mineral density, and osteoblast activity. The appearance of the femoral head did not change significantly in the early stage of osteonecrosis of the femoral head. However, osteoblast and osteoclast activities had already changed in different regions of the osteonecrotic femoral head, which may lead to eventual collapse of the femoral head. Therefore, osteonecrosis of the femoral head must be treated during the early stage. In addition, osteoblast activity should be promoted and osteoclast activity inhibited as early as possible to prevent collapse of an osteonecrotic femoral head.Entities:
Keywords: Early-stage osteonecrosis; femoral head; micro-CT; osteoblast; osteoclast
Mesh:
Year: 2018 PMID: 29483834 PMCID: PMC5821037 DOI: 10.7150/ijbs.18334
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1Structural analysis of early stage femoral head. osteonecrosis (A) Gross appearance of the femoral head. Although the femoral head does not collapse during the early stage of osteonecrosis, a clear necrotic area could be found in the femoral head (red line). Parts I, II, and III were used to make non-decalcified bone tissue pathological sections, detect molecular biology markers, and prepare paraffinized pathological sections, respectively. (B) Micro-computed tomography images (red arrows: microfractures). (C, D, E, and F) Two-dimensional reconstruction and three-dimensional (3D)-rendered images of different regions. (C) Subchondral bone region (red arrow: microfracture). (D) Necrotic region. (E) Sclerotic region. (F) Healthy region. (G-J) Bone histomorphometric data. (G) Bone mineral density (BMD). (H) Trabecular number 3D (Tb.N.3D). (I) Trabecular separation 3D (Tb.Sp.3D) (J) Trabecular thickness 3D (Tb.Th.3D). n = 8 for each group. All data are means ± SDs of those of three independent experiments. **P < 0.05 compared with the healthy region.
Figure 2Results of the pathological sections of early stage osteonecrotic femoral heads. (A) Non-decalcified bone pathological sections. (B-E) Decalcified bone pathological sections. (B) Subchordral bone region. (C) Necrotic region. (D) Healthy region. (E) Sclerotic region. The white arrow in C indicates empty lacunae.
Figure 3Immunofluorescent staining. (A--D) Receptor activator of nuclear factor-κB (RANK), (E-H) receptor activator of nuclear factor-κB ligand (RANKL), (I-L) osteoprotegerin (OPG), and (M-P) bone morphogenetic protein-2 (BMP2) expression levels in different regions of early stage osteonecrotic femoral heads. (A, E, I, M) Subchordral bone region. (B, F, J, N) Necrotic region. (C, G, K, Q) Sclerotic region. (D, H, L, P) Healthy region. White arrows in B and F indicate the expression of RANK and RANKL. Red arrows in K and O indicate the expression of OPG and BMP2.
Figure 4Tartrate-resistant acid phosphatase (TRAP) and alkaline phosphatase staining (ALP) staining. TRAP staining (A) Non-decalcified bone tissue pathological section. Paraffin sections. (B) Subchordral bone region. (C) Necrotic region. (D) Healthy region. (E) Sclerotic region. ALP staining (F) Subchordral bone region. (G) Necrotic region. (H) Healthy region. (I) Sclerotic region. (J, K) The numbers of osteoblasts and osteoclasts. N = 8 for each group. All data are the means ± SDs of those of three independent experiments. **P < 0.05 compared with the healthy region. White arrows in A and C indicate TRAP-positive regions. The red arrow in I indicates an ALP-positive region.
Figure 5PCR and Western blot results. Relative mRNA levels of BMP2 (A), OPG (B), receptor activator of nuclear factor-κB ligand (RANKL) (C) and receptor activator of nuclear factor-κB (RANK) (D) in the subchondral bone, necrotic, sclerotic, and healthy regions. The ratio of RANKL/OPG(E). The expression levels of OPG, BMP2, RANK and RANKL in different regions of the osteonecrotic femoral head (F).